Cardiac Myosins

12/01/2009 - "These studies suggest that cardiac myosin activators offer the promise of a safe and effective treatment for heart failure. "
09/06/2011 - "Heart failure: Cardiac myosin activator shows promise in phase II trial."
01/01/2023 - "This study revealed that cardiac myosin isolated from patients with ischemic heart failure had reduced mechanical activity, which correlated with the impaired clinical phenotype of the patients. "
01/01/2020 - "Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial."
01/01/2017 - " mecarbil (OM) is a cardiac myosin activator that is currently in clinical trials for heart failure treatment. "

06/20/2014 - "This study involved experimental autoimmune myocarditis (EAM) induced with cardiac myosin heavy chain (Myhc)-α 334-352 in A/J mice; the affected animals develop lymphocytic myocarditis but with no apparent clinical signs. "
12/01/2013 - "In this study, we used a rat model of cardiac myosin-induced experimental autoimmune myocarditis to test the effects of ML diet (MLD) (5%) on various markers of cardiac remodeling and function. "
11/01/1993 - "To study the role of CD4+ and CD8+ T cell subsets in T cell-dependent autoimmunity, mice lacking CD4 or CD8 molecules after gene targeting were injected with cardiac myosin to induce organ specific autoimmune myocarditis. "
11/08/2023 - "The experimental autoimmune myocarditis (EAM) mouse model was established by immunization with a fragment of cardiac myosin in Balb/c mice. "
03/05/2023 - "Therefore, purified cardiac myosin was subcutaneously injected to mice to establish the experimental autoimmune myocarditis (EAM) model. "

01/01/2022 - "Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter."
10/25/2023 - "The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review."
10/25/2023 - "We aimed to assess the overall clinical impact of cardiac myosin inhibitors in hypertrophic cardiomyopathy (HCM). "
10/25/2023 - "Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy."
06/16/2023 - "To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). "

08/20/2011 - "Decreases in myocardial contractility and shortening of ventricular systole are characteristic of systolic heart failure and might be improved by a new therapeutic class, cardiac myosin activators. "
02/01/2020 - "As a novel cardiac myosin activator, Omecamtive Mecarbil (OM) has shown promising results in the management of systolic heart failure in clinical examinations. "
01/01/2021 - "Cardiac Myosin Activation for the Treatment of Systolic Heart Failure."
07/07/2017 - "Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure."
10/01/2016 - "Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?"

01/01/2000 - "To study whether there was an anti-cardiac myosin antibody (AMA) in serum of patients with myocardial infarction (AMI), relationship between AMA and the prognosis in patients with AMI was investigated. "
09/01/1987 - "The purpose of our study was to evaluate the effectiveness of a fibrinolytic treatment administered in the acute phase of myocardial infarction by measuring in the plasma, the circulating fragments of human cardiac myosin. "
02/08/2006 - "Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction."
06/01/2005 - "BiELSIA detected cardiac myosin heavy chain fragments in sera of patients obtained at the time of emergency department admission for acute myocardial infarction, but not in normal sera. "
01/01/2000 - "Effect of anti-cardiac myosin antibody on prognosis of patients with acute myocardial infarction."